NIH Analysis of Anti-Cancer Chemicals 2017-2022

The NIH Analysis of Anti-Cancer Chemicals Master IDIQ (2017-2022) is a federal contract vehicle managed by the Pharmaceutical Resources Branch (PRB) of the National Cancer Institute's Developmental Therapeutics Program. The primary objective is to procure specialized analytical services for evaluating bulk drug substances and formulated drug products intended for anti-tumor research. These comprehensive analytical services support critical pharmaceutical development processes, including biological activity screening, pharmacological studies, toxicological assessments, formulation research, and clinical trial preparation. The contract facilitates the generation of detailed analytical reports that will be submitted to the Food and Drug Administration (FDA) as part of Investigational New Drug (IND) filings for emerging anti-tumor agents.

Task orders under this Master IDIQ consistently focus on precise chemical and pharmaceutical analyses, with typical values ranging from approximately $7,000 to $70,000 per delivery order. The task orders frequently involve specific analytical protocols such as appearance assessment, proton NMR, infrared spectroscopy, HPLC analysis (including assay and impurity profiling), moisture content determination, and heavy metal testing. Most task orders are awarded on a Cost Plus Fixed Fee pricing model and do not utilize specific small business set-asides. The contract's period of performance spans from July 31, 2017, to July 31, 2022, with individual task orders typically lasting between three to nine months. While specific prime contractors are not clearly identified in the provided documentation, the work appears to involve specialized scientific research organizations capable of conducting advanced pharmaceutical analytical services for cancer research applications.